Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) Equity Average (2022 - 2025)

Bioregenx's Equity Average history spans 4 years, with the latest figure at -$4.1 million for Q4 2025.

  • Quarterly results put Equity Average at -$4.1 million for Q4 2025, down 180.38% from a year ago — trailing twelve months through Dec 2025 was -$4.1 million (down 180.38% YoY), and the annual figure for FY2025 was -$4.0 million, down 45.24%.
  • Equity Average for Q4 2025 was -$4.1 million at Bioregenx, down from -$3.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $14.7 million in Q2 2024 to a low of -$4.1 million in Q4 2025.
  • The 4-year median for Equity Average is -$1.9 million (2022), against an average of $838217.5.
  • The sharpest move saw Equity Average tumbled 2560.67% in 2023, then skyrocketed 686.61% in 2024.
  • Year by year, Equity Average stood at -$1.4 million in 2022, then plummeted by 78.76% to -$2.4 million in 2023, then skyrocketed by 309.09% to $5.1 million in 2024, then plummeted by 180.38% to -$4.1 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at -$4.1 million, -$3.7 million, and -$3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.